

Experiences of the BPR ...an Industry perspective

5th PCD Industry Symposium on Biocidal Products 29 May 2025 | Celbridge Boris Van Berlo

Membership

FOR TWENTY-TWENTYTHREE



Company Members



Trade Association Members



National Federation Members

WHO WE ARE

Biocides for Europe, formerly known as EBPF (European Biocidal Products Forum), is a Sector Group of Cefic, the European Chemical Industry Council representing the biocides industry in Europe.

WHAT WE DO

We represent the European biocides industry to Authorities such as the European Commission, ECHA and national Competent Authorities.

Biocides for Europe also provides a forum to establish common positions to inform ongoing debates with authorities and other stakeholders at the regulatory, technical and scientific level.

CONTACT

Biocides for Europe Rue Belliard 40 1040 Brussels-Belgium



Visit our homepage on the web at www.biocidesforeurope.org



A sector group of Cefic

European Chemical Industry Council - Cefic aisbl EU Transparency Register n° 64879142323-90



1. Art. 95(5) BPR data protection expiry

2. Product authorization after AS approval



1. Art. 95(5) BPR data protection expiry

2. Product authorization after AS approval





Data protection?

What is it?

The temporary right of the owner of a test or study report to prevent it being used for the benefit of another applicant without suitable cost sharing

Why is it important?

Allows companies making significant investments in data to support the safety and efficacy of (active) substances to have a limited period of protection to make a return on their investments

- Prevents free riding
- Supports level playing field





Protection period for the data shall start when they are submitted for the first time

Data protected under Art. 60 or for which the protection period under Art. 60 has expired shall not be protected again






Protection period for the data shall start when they are submitted for the first time

Data protected under Art. 60 or for which the protection period under Art. 60 has expired shall not be protected again

Protection period for the submitted data shall end X years from the first day of the month following the date of adoption of a decision

In accordance with Art. 9 or Art. 14(4) as relevant (approval or renewal)





Article 60 (2)

The protection period for data submitted with a view to the approval of an existing active substance shall end 10 years from the first day of the month following the date of adoption of a decision in accordance with Article 9 on the approval of the relevant active substance for the particular product-type.





Article 60 (2)

The protection period for data submitted with a view to the approval of an existing active substance shall end 10 years from the first day of the month following the date of adoption of a decision in accordance with Article 9 on the approval of the relevant active substance for the particular product-type.

Article 95 (5)

By way of derogation from Article 60, all data protection periods for active substance/product-type combinations listed in Annex II to Regulation (EC) No 1451/2007, but for which a decision on inclusion in Annex I to Directive 98/8/EC was not taken before 1 September 2013, shall end on 31 December 2025.





Article 60 (2)

The protection period for submitted with a view to the ap of an existing active substance end 10 years from the first day month following the date of ad of a decision in accordance with 9 on the approval of the relevant substance for the particular pr type.



Article 95 (5)

derogation from Article 60, protection periods for active /product-type combinations nnex II to Regulation (EC) No 7, but for which a decision on a Annex I to Directive 98/8/EC taken before 1 September I end on 31 December 2025.





Other regulations

Plant Protection Products Regulation (EC) 1107/2009

Test and study reports -> data protection* of **10 years from the date of first authorisation** (13 years for low-risk plant protection products)

REACH (EC) 1907/2006

Study summaries and robust study summaries submitted in the framework of a registration -> 12 years data protection from the date of the submission

No hard-stop

Equal and fair treatment of all players for any new data generated and submitted at any time!





Data protection hard-stop

Initial intention of the legislator

Art. 60(2): 10 years data protection from first day of the month following the date of adoption of a decision on the approval of the active substance

Art. 89(1): end RP = 14/05/2014

Art. 95(1): derogation from Art. 60(2), data protection all not yet approved RP AS ends = 31/12/2025

BPR Initial Text
Directive 2009/107/EC





Data protection hard-stop - historical error

Initial intention of the legislator

Art. 60(2): 10 years data protection from first day of the month following the date of adoption of a decision on the approval of the active substance

Art. 89(1): end RP = 14/05/**2014**

Art. 95(1): derogation from Art. 60(2), data protection all not yet approved RP AS ends = 31/12/2025

BPR Amendment (2013 & 2014)

Art. 60(2): 10 years data protection from first day of the month following the date of adoption of a decision on the approval of the active substance

Art. 89(1): end RP = 31/12/2024

Art. 95(5): derogation from Art. 60(2), data protection all not yet approved RP AS ends = 31/12/2025

BPR Initial Text
Directive 2009/107/EC

BPR Consolidated Text
Regulation (EU) No 736/2013
Regulation (EU) No 334/2014





Data protection hard-stop - historical error leading to mismatch

Initial intention of the legislator

Art. 60(2): 10 years data protection from first day of the month following the date of adoption of a decision on the approval of the active substance

Art. 89(1): end RP = 14/05/**2014**

Art. 95(1): derogation from Art. 60(2), data protection all not yet approved RP AS ends = 31/12/2025

BPR Amendment (2013 & 2014)

Art. 60(2): 10 years data protection from first day of the month following the date of adoption of a decision on the approval of the active substance

Art. 89(1): end RP = 31/12/2024

Art. 95(5): derogation from Art. 60(2), data protection all not yet approved RP AS ends = 31/12/2025

Recent extension RP (2024)

Art. 60(2): 10 years data protection from first day of the month following the date of adoption of a decision on the approval of the active substance

Art. 89(1): end RP = 31/12/**2030**

Art. 95(5): derogation from Art. 60(2), data protection all not yet approved RP AS ends = 31/12/2025

BPR Initial Text
Directive 2009/107/EC

<u>BPR Consolidated Text</u> <u>Regulation (EU) No 736/2013</u> <u>Regulation (EU) No 334/2014</u> 3rd extension RP





Data protection and the Review Programme - the intention

Data protection hard-stop in December 2025

If Review Programme finalised by 2014 as intended in the initial BPR text





Data protection and the Review Programme - the intention

Data protection hard-stop in December 2025

If Review Programme finalised by 2014 as intended in the initial BPR text



> 10 years between both end-dates

All existing active substances

would benefit from foreseen

10 years data protection

according to Art. 60 BPR





Data protection hard-stop in December 2025
Review Programme not finalised in 2014 - extended to 2024 - still not finalised





Data protection hard-stop in December 2025 Review Programme not finalised in 2014 - extended to 2024 - still not finalised



< to << 10 years between both end-dates

Only 27% existing active substances*

has benefitted from foreseen 10 years data protection according to Art. 60 BPR





Data protection hard-stop in December 2025 Review Programme not finalised in 2024 - extended to 2030 - only 50% finalised





Data protection hard-stop in December 2025 Review Programme not finalised in 2024 - extended to 2030 - only 50% finalised




Moving goalposts

High number of requests for new data that will not benefit from any data protection at all

(including ED data, but not exclusively)











Consequences

No data protection

BPR objective of high-level protection compromised

Effortless and costless Art 95 listing

Unlevel playing field





Article 95 listing after 2025


Effortless and costless Article 95 listing

Article 95 (1)


...A person established within the Union who manufactures or imports a relevant substance, on its own or in biocidal products ('the substance supplier') or who manufactures or makes available on the market a biocidal product consisting of, containing or generating that relevant substance ('the product supplier'), may at any time submit to the Agency either a complete substance dossier for that relevant substance, a letter of access to a complete substance dossier, or a reference to a complete substance dossier for which all data protection periods have expired...




Free riding re-introduced



Safety goal BPR compromised



Safety goal BPR compromised





Safety

(3) The purpose of this Regulation is to improve the free movement of biocidal products within the Union while ensuring a high level of protection of both human and animal health and the environment...



Level playing field

(58) A level playing field should be established as quickly as possible on the market for existing active substances...







(3) The purpose of this Regulation is to improve the free movement of biocidal products within the Union while ensuring a high level of protection of both human and animal health and the environment...



Level playing field

(58) A level playing field should be established as quickly as possible on the market for existing active substances...







Uncompliant sources
Unknown (level of) impurities
TE delayed due to RP delays

protection of both human and animal health and the environment...



Level playing field

(58) A level playing field should be established as quickly as possible on the market for existing active substances...







Uncompliant sources
Unknown (level of) impurities
TE delayed due to RP delays

protection of both human and animal health and the environment...









Uncompliant sources
Unknown (level of) impurities
TE delayed due to RP delays

protection of both human and animal health and the environment...



Re-introduction of free-riding
Harms BPR compliant companies
Facilitates unfair competition





"Cry wolf" or exaggeration ...?

- Free riding existed under BPD
- Back in 2014, "a MS reported that according to a recent survey of their market, 90% of biocidal products placed on their market contain an active substance, the manufacturer of which is not listed in accordance with Article 95"*
- Third parties approached our members for LoA but no continuation due to the cost of it
- Third parties approached our members for LoA but no continuation due to no chemical similarity
- In consortia, participants leave the consortium due to the impending investments in studies (e.g. ED) that with the current situation will not benefit from any data protection This could result in substances not being supported anymore





"Cry wolf" or exaggeration ...?

- Free riding existed under BPD
- Back in 2014, "a MS reported that according to a recent survey of their market, 90% of biocidal products placed on their market contain an active substance, the manufacturer of which is not listed in accordance with Article 95"*
- Third parties approached our members for LoA but no continuation due to the cost of it
- Third parties approached our members for LoA but no continuation due to no chemical similarity
- In consortia, participants leave the consortium due to the impending investments in studies (e.g. ED) that with the current situation will not benefit from any data protection - This could result in substances not being supported anymore

...no, it is a genuine concern!





CORRECTION NEEDED

No hard-stop on 31/12/2025
Realignment with RP extension 31/12/2030
Extend data protection till 31/12/2031



Data included at the submission of the AS/PT dossier (typically 2004-2008)

only for NEW DATA

Data generated under the BPR due to:

- continuously changing/new guidance
- Regulation (EU) 2017/2100 on ED
- BPR Annexes amendments
- redefinition of ASs

•



ACTION NEEDED

Authorities to understand better the importance of data protection and acknowledge the severity of this issue

Equal and fair treatment of all players for any new data generated and submitted under the BPR

No hard-stop on 31/12/2025


Work together to solve this unfair situation

MSs & IND to convince COM to use the most appropriate legal and regulatory tool to ensure BPR studies have data protection matching the extended length of the Review Programme... as it was initially intended





Take home messages









1. Art. 95(5) BPR data protection expiry

2. Product authorization after AS approval





Review Programme still ongoing...

...in the meantime, till the AS approval date of a certain AS/PT combination:

National Procedures in Transition Period

- Procedures different in every MS
- Requirements different in every MS
- Obligations different in every MS





Review Programme still ongoing...

...in the meantime, till the AS approval date of a certain AS/PT combination:

National Procedures in Transition Period

- Procedures different in every MS
- Requirements different in every MS
- Obligations different in every MS

From the AS approval date onwards

- Only BPR authorisation procedures for that AS/PT combination
- Applications need to be made <u>before</u> AS approval date to stay on the market during evaluation!





General tips for applicants

Start to prepare well in advance of approval date!

- Find eCA/refMS and get written confirmation of their commitment to act as such
- Request pre-submission meeting(s) with eCA/refMS
- Get external help if necessary
- Consciously choose your preferred Biocidal Product (BP) application-type
- Build your dossier using all relevant ECHA IT Tools & templates
- Be aware of all requirements & most recent applicable guidance
- Stay in contact/communicate with your eCA/refMS






National Authorisation (NA) - Art. 29-31 BPR

If you are only interested in <u>one single local</u> market

Payment: 30 days

• Validation: 30d + 90d stop the clock + 30d








National Authorisation (NA) - Art. 29-31 BPR

If you are only interested in <u>one single local</u> market

- Payment: 30 days
- Validation: 30d + *90d stop the clock* + 30d
- Evaluation: 365d + 180d stop the clock
- Including 30d commenting period applicant on draft PAR
- Finalisation: grant/refuse authorization

Single product or Biocidal Product Family







Mutual Recognition in Parallel (MRP) - Art. 34 BPR

If you are interested in <u>several markets</u>

Submitted at same time as NA

- Payment: 30 days
- Validation: 30d + *90d stop the clock* + 30d
- Evaluation: 365d + 180d stop the clock
- Including 30d commenting period applicant on draft PAR

COMPETENT APPLICANT AUTHORITY Additional Draft assessment report information if requested REFERENCE AND REFERENCE CONCERNED COMPETENT COMPETENT AUTHORITY AUTHORITY APPLICANT Decision on the Final draft AR and draft product 30 days to provide SPC are sent to applicant authorisation subject to written comments and cMSCA trough R4BP 3 mutual recognition In case of disagreement the case is referred to Coordination Group the Coordination Group

REFERENCE





Mutual Recognition in Parallel (MRP)

If you are interested in <u>several markets</u>

Mutual Recognition Phase (90d)

- 1st step: 40d cMS commenting period
- 2nd step: 50d bilateral exchange
- If agreement on PAR & SPC: 30d to grant authorisation
- If no agreement on PAR & SPC: submission of referral to Coordination Group (CG)

AUTHORITY Additional Draft assessment report information if requested REFERENCE AND REFERENCE CONCERNED COMPETENT AUTHORITY AUTHORITY APPLICANT Decision on the Final draft AR and draft product 30 days to provide SPC are sent to applicant authorisation subject to written comments and cMSCA trough R4BP 3 mutual recognition In case of disagreement the case is referred to Coordination Group the Coordination Group

REFERENCE

APPLICANT





Mutual Recognition in Parallel (MRP)

If you are interested in several markets

CG Referral Procedure (60d) - Art. 35-36 BPR

- Discussion in CG (during meeting, teleconference or written procedure)
- Applicant should be heard
- If agreement after 60d: finalisation by granting/refusing authorisation
- If no agreement: referral of disagreement to COM according to Art. 36 BPR

COM to adopt decision (implementing act) Possibility to ask ECHA opinion according to Art. 38 BPR

AUTHORITY Draft assessment report information if REFERENCE AND REFERENCE CONCERNED COMPETENT COMPETENT AUTHORITY AUTHORITY APPLICANT Decision on the Final draft AR and draft product 30 days to provide SPC are sent to applicant authorisation subject to written comments and cMSCA trough R4BP 3 mutual recognition In case of disagreement Coordination Group the case is referred to the Coordination Group

REFERENCE COMPETENT

APPLICANT

Additional

requested

Cefic sector group **



Mutual Recognition in Sequence (MRS) - Art. 33 BPR

If already existing NA in a MS and you are interested in <u>additional market(s)</u>

Submitted at any time

• Payment: 30 days

Validation: 30d

Mutual recognition phase: 90d

Procedure similar to MRP

REFERENCE AND CONCERNED COMPETENT AUTHORITY

Decision on the product authorisation subject to mutual recognition

In case of disagreement the case is referred to the Coordination Group

Coordination Group





Union Authorisation (UA) - Art. 41-46 BPR

If you are interested in whole EU market or substantial amount of markets

- Decision by COM (implementing act) after BPC peer-review & BPC opinion
- For BP with similar conditions of use across the EU (soon new guidance + template for applicants!)
- Highly recommended to perform ECHA pre-submission application for UA (adaptations expected!)
- Not for BP containing AS meeting exclusion criteria
- Not for BP of PT 14, 15, 17, 20 & 21
- Had sequential start-up: last phase 1 January 2020, so now available for all other PTs
- Fee for ECHA (submission + annual fee) & fee for eCA
- Possible for single product or for Biocidal Product Family






Union Authorisation (UA)

If you are interested in <u>whole EU market</u> or substantial amount of markets

- Payment ECHA: 30d
- Acceptance ECHA
- Validation eCA: 30d + 90d stop the clock + 30d
- Payment eCA: 30d (part of validation)
- Acceptance eCA







Union Authorisation (UA)

If you are interested in <u>whole EU market</u> or substantial amount of markets

- Evaluation eCA: 365d + 180d stop the clock
- Including 30d commenting period applicant
- eCA submits draft PAR & SPC to ECHA
- Peer-review process: 180d
- WG discussion possible
- BPC opinion mandatory








Union Authorisation (UA)

If you are interested in <u>whole EU market</u> or substantial amount of markets

- ECHA submits BPC opinion & final PAR to COM
- SPC translation in all official languages of EU: 30d
- If UA granted: COM to adopt implementing regulation
- If UA not granted: COM to adopt implementing decision







Simplified Authorisation (NA) - Art. 25-27 BPR

To encourage the use of less harmful BPs

BP to comply with all these conditions:

- AS on Annex I BPR (& comply to specified restrictions)
- Not containing substances of concern (SoC)
- Not containing nanomaterials
- Demonstrate sufficient level of efficacy
- Not requiring any personal protective equipment (PPE) for intended use & handling





Simplified Authorisation (NA)

Procedure similar to NA

- Shorter timelines
 - > Payment: 30d
 - > Evaluation: 90d + 90d stop the clock + 90d
 - > Finalisation: grant/refuse authorization
- Different/lower data requirements
- Can be made available on MS markets without need for MR
 - ➤ Notification 30 days before placing BP on MS market

ECHA APPLICANT Format check Payment of fees EVALUATING COMPETENT AUTHORITY Dossier assessment and product authorisation EVALUATING COMPETENT **AUTHORITY APPLICANT** Dossier assessment and Additional information if product authorisation requested





Same Biocidal Products Authorisation (SBP)

Regulation (EU) 414/2013


amended by Regulation (EU) 2016/1802

currently under new amendment (expected soon)

- For identical products
- For identical Biocidal Product Families
- To reduced authorisation
- To reduced market (UA → NA)

Same Biocidal Product has always different authorisation number than reference product

Authorisation options







Same Biocidal Product of NA

Reference product has been authorised by NA or is subject of authorisation application

- Adapted data requirements
- eCA validation: 30d
 - Check that differences between same product and reference product is only info which can be subject of an administrative change (<u>(EU) No 354/2013</u>)
- eCA to grant/refuse authorisation: 60d
 - Either from validation
 - Either from adoption decision concerning the reference product





Same Biocidal Product of NA

Reference product has been authorised by NA or is subject of authorisation application

- Adapted data requirements
- eCA validation: 30d
 - Check that differences between same product and reference product is only info which can be subject of an administrative change (<u>(EU) No 354/2013</u>)
- eCA to grant/refuse authorisation: 60d
 - Either from validation
 - Either from adoption decision concerning the reference product

Same Biocidal Product of UA

Reference product has been authorised by UA or is subject of authorisation application

- Adapted data requirements
- ECHA validation: 30d
 - Check that differences between same product and reference product is only info which can be subject of an administrative change (<u>(EU) No 354/2013</u>)
- ECHA to prepare opinion and send to COM: 30d
 - Either from validation
 - Either from date submission opinion on reference product





Biocidal Product Family

Union Authorisation

Same Biocidal Products






Biocidal Product Family

Union Authorisation

Same Biocidal Products





Biocidal Product Family

Union Authorisation

Same Biocidal Products




Revision BPF concept New guidance





Biocidal Product Family



Union Authorisation




Same Biocidal Products

Revision BPF concept New guidance






Biocidal Product Family



Revision BPF concept
New guidance

Union Authorisation




Uncertainty
Unpredictability
? Higher ECHA fees?
? New procedure
similar conditions of use?

Same Biocidal Products






Biocidal Product Family




Revision BPF concept New guidance

Union Authorisation



Uncertainty
Unpredictability
? Higher ECHA fees?
? New procedure
similar conditions of use?


Same Biocidal Products








Biocidal Product Family



Revision BPF concept
New guidance

Union Authorisation



Uncertainty
Unpredictability
? Higher ECHA fees ?
? New procedure
similar conditions of use ?

Same Biocidal Products



Ongoing amendment SBP Regulation



Take home messages

Start to prepare well in advance of approval date!

- Get external help if necessary
- In particular for SMEs: explore authorisation through SBP or as part of a Biocidal Product Family
- Explore if your AS supplier can assist you
- Explore if a product consortium exists for your type of products
- If it does not exist, consider setting-up a product consortium with some peers





Take home messages

Start to prepare well in advance of approval date!

- Get external help if necessary
- In particular for SMEs: explore authorisation through SBP or as part of a Biocidal Product Family
- Explore if your AS supplier can assist you
- Explore if a product consortium exists for your type of products
- If it does not exist, consider setting-up a product consortium with some peers

Be aware

- Not easy to find an eCA for your UA or a refMS for your NA!
- Everything goes smoother with a complete and high quality dossier!

Start to prepare well in advance of approval date!







